date,title,source
Oct-25-18,"Concert Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 1, 2018",Business Wire
Nov-01-18,Edited Transcript of CNCE earnings conference call or presentation 1-Nov-18 12:30pm GMT,Thomson Reuters StreetEvents
Nov-01-18,Concert: 3Q Earnings Snapshot,Associated Press
Nov-01-18,Concert Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Company Update,Business Wire
Nov-05-18,"Concert Pharmaceuticals Presents Preclinical Data on CTP-692, a Novel Drug Candidate for Schizophrenia, Supporting Potential to Improve Safety Profile of D-Serine",Business Wire
Nov-05-18,Edited Transcript of CNCE earnings conference call or presentation 1-Nov-18 12:30pm GMT,Thomson Reuters StreetEvents
Nov-06-18,Edited Transcript of CNCE earnings conference call or presentation 1-Nov-18 12:30pm GMT,Thomson Reuters StreetEvents
Nov-07-18,Concert Pharmaceuticals to Participate at Upcoming Investor Conferences,Business Wire
Nov-12-18,"Report: Exploring Fundamental Drivers Behind Sterling Construction, Tredegar, j2 Global, Medical Transcription Billing, Concert Pharmaceuticals, and Senseonics  New Horizons, Emerging Trends, and Upcoming Developments",GlobeNewswire
Nov-12-18,Concert Pharmaceuticals Reports Positive CTP-543 Results from Interim Analysis of Phase 2a Trial in Patients with Alopecia Areata,Business Wire
Nov-26-18,Should You Be Concerned About Concert Pharmaceuticals Incs (NASDAQ:CNCE) Historical Volatility?,Simply Wall St.
Nov-28-18,Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed,Zacks
Dec-17-18,Concert Pharmaceuticals Initiates Phase 1 Clinical Program of CTP-692 for the Treatment of Schizophrenia,Business Wire
Jan-02-19,"How Much Are Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Insiders Spending On Buying Shares?",Simply Wall St.
Jan-22-19,Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata,Business Wire
Jan-24-19,Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia,Business Wire
Feb-05-19,Mizuho's 9 Best Biotech Stocks to Buy for 2019,Kiplinger
Feb-11-19,Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting,Business Wire
Feb-12-19,"Analysis: Positioning to Benefit within Masco, Ascena Retail Group, Leidos, NetScout, MYR Group, and Concert Pharmaceuticals  Research Highlights Growth, Revenue, and Consolidated Results",GlobeNewswire
Feb-13-19,"Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): Time For A Financial Health Check",Simply Wall St.
